Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised nearly $100 million in Series C round led by Hong Kong-listed contrast research organisation (CRO) Tigermed and Shanghai-based Yingke PE.
Additional contributions came from ATCG Holdings, ICBC Asset Management, and two funds affiliated with Yingke PE, according to a statement. Founded in Hangzhou in 2016, Adlai established itself as a...
China Ping An Insurance Overseas Holdings has aspirations to manage assets for third-party investors. Spinning out part of the global private equity portfolio may help it get there
Buoyed by strong macro fundamentals and robust returns, Japan’s buyout managers continue to attract capital while most other strategies across Asia struggle. Will this popularity be sustained?
Zhenkunhang, a China-based distribution platform for industrial products, has raised $315 million Series E funding led by YF Capital - previously Yunfeng Capital - a private equity firm co-founded by Alibaba’s Jack Ma.
Japanese logistics technology start-up Openlogi has raised JPY1.7 billion ($16.7 million) in an ongoing Series C round featuring Sumitomo Corporation.